Rising Market Shares for Omliclo and Yuflyma in Major Countries

Sales Expansion Expected in the Second Half Amid Bidding Rounds and Inventory Demand

Celltrion’s high-margin follow-up product lineup is demonstrating stable growth across Europe, increasing its market influence. Given the European pharmaceutical market's tendency for higher supply in the second half of the year, the company expects this growth to accelerate even further toward the end of the year.


According to Celltrion and pharmaceutical market research firm IQVIA on July 10, Omliclo (ingredient: omalizumab), a treatment for chronic spontaneous urticaria launched in Europe in September last year, achieved a market share of approximately 16% as of the first quarter of this year.


In particular, in Spain—one of the major five European countries (EU5)—it recorded a market share of about 71%. Omliclo has also rapidly expanded its presence in other key European markets, such as Portugal (47%), Ireland (41%), and Norway (31%). This has been attributed not only to its first-mover advantage but also to the country-specific direct sales strategies led by local subsidiaries in Europe.


Incheon Songdo, view of Celltrion Plant 2. Photo by Hyunmin Kim

Incheon Songdo, view of Celltrion Plant 2. Photo by Hyunmin Kim

View original image

Vegzelma (ingredient: bevacizumab), a treatment for metastatic colorectal cancer and breast cancer, also achieved a market share of around 28% in Europe during the same period, maintaining the number one position in the bevacizumab market for 21 consecutive months. Vegzelma has recently been listed in major PBM formularies in the United States, including ESI and Optum, earning recognition for its product strength in both of the world’s largest markets. As a result, it is expected to drive Celltrion’s next-generation revenue growth.


Yuflyma (ingredient: adalimumab), a treatment for autoimmune diseases, also maintained the top prescription spot in the European adalimumab market for a full year with a share of about 22%. This performance is particularly notable in EU5 countries with significant market influence, such as the United Kingdom (49%) and Italy (46%).


Stekima (ingredient: ustekinumab), another high-margin follow-up product, achieved a market share of about 9%, continuing its growth every quarter. Prescription expansion is being driven mainly in countries like Portugal (41%), Sweden (28%), and Italy (20%). In addition, active bundling sales with other autoimmune disease products are maximizing synergies across the product portfolio.


To maximize the performance of its high-margin product lineup, Celltrion plans to increase its local sales workforce and strengthen its sales capabilities. The company also intends to actively pursue marketing activities targeting key opinion leader (KOL) groups, including participation in major global conferences such as the European Respiratory Society (ERS) and United European Gastroenterology Week (UEGW).


Celltrion expects the high-margin follow-up product lineup to achieve even steeper growth through the end of the year, backed by characteristics unique to the European pharmaceutical market. These factors include concentrated bidding in major European countries during the second and third quarters, the introduction of initial supplies following successful bids, and increased year-end pharmaceutical inventory purchases compared to the beginning of the year.



A company representative stated, "With large-scale bids scheduled to continue in major countries, we will make every effort in the second half of the year to expand sales and achieve performance growth through these opportunities."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing